Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Nrx Pharmaceuticals Inc (NRXP)

Nrx Pharmaceuticals Inc (NRXP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 575,382
  • Shares Outstanding, K 53,774
  • Annual Sales, $ 0 K
  • Annual Income, $ -430 K
  • 60-Month Beta 0.02
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade NRXP with:

Options Overview

Details
  • Implied Volatility 167.82%
  • Historical Volatility 128.20%
  • IV Percentile 50%
  • IV Rank 26.61%
  • IV High 230.86% on 08/12/21
  • IV Low 144.96% on 08/25/21
  • Put/Call Vol Ratio 0.20
  • Today's Volume 5,085
  • Volume Avg (30-Day) 5,910
  • Put/Call OI Ratio 0.27
  • Today's Open Interest 20,326
  • Open Int (30-Day) 8,329

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.00 +7.00%
on 09/17/21
18.30 -41.53%
on 08/18/21
-1.77 (-14.19%)
since 08/17/21
3-Month
8.39 +27.53%
on 07/16/21
26.24 -59.22%
on 07/23/21
-5.08 (-32.19%)
since 06/17/21
52-Week
8.39 +27.53%
on 07/16/21
76.99 -86.10%
on 12/22/20
+0.02 (+0.19%)
since 09/17/20

Most Recent Stories

More News
IQVIA (IQV) Announces Collaboration With NRx Pharmaceuticals

IQVIA (IQV) and NRx are set to work closely to support activities essential for emergency use authorization of ZYESAMI.

EFX : 268.49 (-2.01%)
G : 49.13 (-1.68%)
IQV : 256.33 (-0.59%)
NRXP : 10.70 (+1.90%)
NRx Pharmaceuticals to Participate in H.C. Wainwright 23rd Annual Global Investment Conference

/PRNewswire/ -- NRx Pharmaceuticals (NRx) (Nasdaq: NRXP) today announced that NRx's management team will present and host one-on-one investor meetings at the upcoming H.C. Wainwright Global Investment...

NRXP : 10.70 (+1.90%)
Relief Reports that U.S. Collaboration Partner has Announced a New Finding from Aviptadil Phase 2b/3 Trial Demonstrating Clinically Significant Relief from Respiratory Distress in Critical COVID-19

GENEVA, SWITZERLAND / ACCESSWIRE / August 31, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic relief from...

RLFTF : 0.1591 (+1.27%)
NRXP : 10.70 (+1.90%)
NRx Pharmaceuticals Announces New Finding from ZYESAMI™ (aviptadil) Phase 2b/3 Clinical Trial Demonstrating Clinically Significant Relief from Respiratory Distress in Critical COVID-19

/PRNewswire/ -- NRx Pharmaceuticals (NRx) (Nasdaq: NRXP) announced an additional finding in its phase /3 clinical trial investigating ZYESAMI™ (aviptadil) for the treatment of patients with acute Respiratory...

NRXP : 10.70 (+1.90%)
NRx Pharmaceuticals to Work with Cardinal Health to Ensure Efficient Distribution of Potential Therapies

/PRNewswire/ -- NRx Pharmaceuticals (NRx) (Nasdaq: NRXP) announced today it has signed an agreement with Cardinal Health to provide third party logistics and distribution of ZYESAMI™ upon the potential...

NRXP : 10.70 (+1.90%)
NRx Pharmaceuticals Announces Closing of $30 Million Private Placement

/PRNewswire/ -- NRx Pharmaceuticals (Nasdaq: NRXP), today announced that it has completed its previously announced private placement for the purchase of 2,727,273 shares of common stock. The Company issued...

NRXP : 10.70 (+1.90%)
Participants in High Dose BriLife™ Investigational Vaccine Trial for COVID-19 Advised Booster Not Necessary

/PRNewswire/ -- NRx Pharmaceuticals (NRx) (Nasdaq: ), a clinical stage, biopharmaceutical company noted today reports in the Israeli media that participants in the BriLife vaccine trial who received...

NRXP : 10.70 (+1.90%)
NRx Pharmaceuticals Announces $30 Million Private Placement

/PRNewswire/ -- NRx Pharmaceuticals (NRx) (Nasdaq: NRXP) (or the "Company"), a corporation, today announced that it has entered into definitive agreements with investors to purchase 2,727,273 shares...

NRXP : 10.70 (+1.90%)
Relief Reports that its U.S. Collaboration Partner has Announced a Positive Safety Report for ZYESAMI(TM) (aviptadil) in NIH Sponsored ACTIV-3 Study in Patients with Life-Threatening COVID-19

GENEVA, SWITZERLAND / ACCESSWIRE / August 19, 2021 / RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic relief from...

RLFTF : 0.1591 (+1.27%)
NRXP : 10.70 (+1.90%)
NRx Pharmaceuticals Announces Positive Safety Report for ZYESAMI™ (aviptadil) in NIH Sponsored ACTIV-3 Critical Care Study in Patients with Life-Threatening COVID-19

/PRNewswire/ -- NRx Pharmaceuticals (NRx) (NASDAQ: NRXP), a clinical stage, biopharmaceutical company today provided a safety update on ZYESAMI (aviptadil) which is being tested in the ACTIV-3 Critical...

NRXP : 10.70 (+1.90%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

NRX Pharmaceuticals Inc. is a patient-focused, clinical stage pharmaceutical company. It creates therapies to treat diseases where no medicines currently exist. NRX Pharmaceuticals Inc., formerly known as Big Rock Partners Acquisition Corp., is based in RADNOR, Pa.

See More

Key Turning Points

3rd Resistance Point 11.74
2nd Resistance Point 11.26
1st Resistance Point 10.98
Last Price 10.70
1st Support Level 10.21
2nd Support Level 9.72
3rd Support Level 9.44

See More

52-Week High 76.99
Fibonacci 61.8% 50.78
Fibonacci 50% 42.69
Fibonacci 38.2% 34.60
Last Price 10.70
52-Week Low 8.39

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar